Cookies on the
LGC website
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the LGC website. However, if you would like to, you can change your cookie settings at anytime.
Question markFind out more

Our previous corporate charities

2016-2017: The Motor Neurone Disease Association (MNDA)
 
We were delighted to support MNDA as our corporate charity in 2016-2017. The total amount raised across the LGC Group will be announced soon.
 
The charity’s vision is a world free from MND. It funds and promotes global research that will revolutionise understanding and treatments and bring us closer to a cure for MND. Its patron is Professor Stephen Hawking. MND, also commonly known as amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s Disease in the USA, is a fatal, rapidly progressive disease that attacks the motor neurones, or nerves, in the brain and spinal cord. This means messages gradually stop reaching muscles, which leads to weakness and wasting. MND can leave people locked in a failing body, unable to move, talk, swallow and eventually breathe. One third of people with MND lose their life within 14 months and over half die within two years of diagnosis. It is a swiftly progressive neurological disease that affects over 400,000 of the world’s population and kills over 100,000 every year. Around 5,000 people live with it in the UK.
 
In the last year, the charity was funding 82 research programmes. The charity also awarded two new clinical fellowships, as well as four new Non-Clinical Fellowships. The MND Association has approved 4,057 uses of its unique DNA Bank samples by researchers worldwide. Projects using DNA Bank samples have led to major research developments. MNDA is also especially focused on driving forward global research projectsthe Association and the DNA Bank play a critical role in the Whole Genome Sequencing Project and Project Mine, one of the most ambitious global research projects in this field.

2015-2016: Bloodwise (formerly Leukaemia & Lymphoma Research)
 
We were delighted to support Bloodwise as our corporate charity in 2015-2016. We raised a total of £39,197.02
 
The funds raised by LGC and its employees, are used to support a project looking at how DNA sequencing can be used to personalise treatments in non-Hodgkin lymphomas.
 
Blood cancers currently occur in 25 people in every 100,000 in the developed world which, in proportion, are only exceeded by breast, prostate, lung and colon cancers. 
People with lymphoma produce abnormal lymphocytes, which are one type of white blood cell.  There are two main types of lymphoma; Hodgkin and non-Hodgkin.  Non-Hodgkin lymphoma is more common and is a blood cancer that appears as a solid tumour in the glands, usually of the neck, chest, armpit or groin.  There are 35 different types of non-Hodgkin lymphoma.
By studying DNA, scientists hope to understand the changes that cause normal lymphocytes to develop into lymphoma cells.  They will investigate why these cells may grow too rapidly, live too long, and not develop into mature cells that take part in normal immune reactions.  Once this is understood, drugs may be developed that target the specific gene mutations in the specific type of lymphoma to block this process.

2014-2015 Parkinson’s
We were delighted to support Parkinson’s charity as our corporate charity during 2014-15. We raised a total of £30,323.79
 
The money we raised also went towards an ambitious five year project, ‘Tracking Parkinson’s’, the world’s largest ever in-depth study of people with Parkinson’s, which aims to speed up the search for a cure. The objective of the project is to find biomarkers. At the moment there are no reliable biomarkers for Parkinson’s and without these, diagnosing Parkinson’s accurately or measuring how it progresses cannot be done. This is a collaborative study with researchers worldwide having access to research data and blood samples collected.
 
There are five million people living with Parkinson’s, predicted to rise to over seven million by 2020 around the world. One million Americans live with Parkinson's disease, which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy and Lou Gehrig's disease. 
 
Every hour, someone is diagnosed with Parkinson’s in the UK, a progressive neurological condition that can strike anyone, at any time. Often referred to as a condition that affects the older generation, one in 20 people diagnosed is under the age of 40. People with Parkinson's don't have enough dopamine in the brain. One of the effects of this is slowed movement, making even the simplest task such as making a cup of tea or picking up children, difficult and often painful. Although the cause of Parkinson’s is currently unknown, what is clear is the devastating impact this condition has, not only on the lives of those forced to live with it, but also their loved ones. 


2013/2014 Stroke Association

We were delighted to support the Stroke Association as our corporate charity during 2013-14. We raised a record amount of £35,806.22.

The money raised by LGC will be used to help fund a particular Stroke Association research project, looking at ‘A UK-wide clinical and genetic cohort study of aneurismal, subarachnoid haemorrhage’. This research looks at bleeding in the brain caused by rupture of an abnormal swelling or aneurysm. This can cause a devastating form of stroke known as subarachnoid haemorrhage (SAH), which causes death in about 50%, and dependence in about 20% of people.

Because SAH most often affects younger people, it causes a great deal of disability in people of working age, and often leads to hardship because people frequently can’t work or find a job afterwards. With this stage of research we want to look for genes and other environmental factors (e.g. high blood pressure, smoking) that cause aneurysms to develop and rupture, and also how these factors affect prognosis after SAH. 

cheque-presentation1


2012/2013 – Arthritis UK


LGC was delighted to support Arthritis Research UK during 2012-2013 and raised a record amount of £34,339.65.

Arthritis and musculoskeletal diseases (osteoarthritis, rheumatoid arthritis, lupus, ankylosing spondylitis, polymyalgia rheumatica and back pain to name just a few) are the greatest cause of physical disability in the world. More than one in six people are affected by arthritis and there are 10 million people in the UK alone living with a musculoskeletal condition. Arthritis can affect people of any age – from babies and teenagers to the elderly and every group in between.

Arthritis Research UK is the charity leading the fight against arthritis. It is the biggest funder of research into the cause, treatment and cure of all forms of arthritis in the UK. ARUK is working to take the pain away for people living with all forms of the disease, and to help them remain active, doing the things they love.

As an organisation, ARUK creates the knowledge to change the lives of people with arthritis, from funding research, to educating health care professionals and providing information to people with arthritis and their carers. The charity aims to fund pioneering, high quality research that will develop the best treatment for and prevention of arthritis in the world.

LGC's fundraising in 2012/13 has gone towards the Arthritis Research UK centre for Adolescent Rheumatology.



Arthritis UK collecting a cheque from LGC
Members of the LGC charity committee present a cheque to Arthritis Research UK.


2011/2012 – Muscular Dystrophy Campaign

LGC was delighted to support the Muscular Dystrophy Campaign during 2011-2012.

Muscular Dystrophy and related muscle diseases cause muscle to waste and weaken. More than 70,000 children and adults in the UK have a type of muscle disease or related condition supported by the Muscular Dystrophy Campaign. The severity of the muscle conditions varies enormously - for the most severe disorders, children can die at birth or in their first year of life, while the mildest forms only slightly affect elderly people and have no life-limiting impact.

The Muscular Dystrophy Campaign leads the fight against muscle disease by:
• funding world-class research
• offering free information and advice about care and support
• providing grants towards equipment
• campaigning to raise awareness and bring about change.

LGC raised £22,387.63 for the charity. As a result of LGC’s fundraising efforts, we were announced as the winner of the Muscular Dystrophy Campaign ‘Corporate Partner of the Year Award’.


2010/2011 – UNICEF

In 2010 and 2011 LGC supported UNICEF, specifically their 'Unite' campaign.

UNICEF is the United Nations Children's Fund, founded over 60 years ago to meet the emergency needs of children after the Second World War. It is the leading children's organisation, reaching children in more than 190 countries around the world, and contrary to popular belief, it is not funded by the UN, but rather relies entirely on voluntary contributions to support its programmes worldwide. UNICEF helps to ensure children around the world have basic human rights, including the right to be heard, the right to be treated fairly, the right to an education, the right to be healthy and the right to a childhood.

LGC raised £22,370.63. This money helped to support UNICEF's services for the prevention of mother to child transmission of HIV, which included interventions such as the HIV 'Mother and baby' pack.

Since 2002 LGC has supported a number of other charities including Cancer Research UK, Médecins Sans Frontières, Anthony Nolan Trust, WaterAid, SANE, the Alzheimer’s Society and the Cystic Fibrosis Trust.